Login to Your Account



EASL Roundup


Tuesday, April 5, 2011
Idera Pharmaceuticals Inc., of Cambridge, Mass., presented data from a four-week Phase I trial of IMO-2125 in combination with ribavirin in treatment-naïve hepatitis C virus genotype 1 patients, which showed that the combination was well tolerated and produced clinically meaningful antiviral activity. The drug at all dose levels induced declines in viral levels at 48 hours after the first dose, and the mean viral load reductions at 48 hours after the first dose was 2.5 log10, 1.3 log10 and 1.6 log10 for the 0.16 mg/kg once-weekly dose, the 0.32 mg/kg once-weekly dose and the 0.16 mg/kg twice-weekly dose, respectively.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription